

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2016
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <24	0 to <24 ^b	>=24 ^d	Complete ^e	
Race	Sex									
All Races	Both Sexes	248,946	177,490	117,326	69,109	31,890	644,761	49,943	694,704	
	Males	135,137	94,173	60,159	36,020	16,581	342,069	25,489	367,558	
	Females	113,809	83,317	57,167	33,089	15,309	302,692	24,454	327,146	
White	Both Sexes	213,764	154,454	101,984	60,537	28,026	558,765	49,625	620,368	
	Males	116,527	82,172	52,535	31,627	14,543	297,404	26,526	330,121	
	Females	97,237	72,282	49,448	28,910	13,483	261,361	23,099	290,247	
Black	Both Sexes	20,500	13,640	9,750	5,271	2,215	51,376	4,115	55,491	
	Males	10,712	7,188	4,768	2,684	1,174	26,526	1,911	28,437	
	Females	9,789	6,452	4,981	2,587	1,041	24,850	2,204	27,054	
Asian/ Pacific Islander	Both Sexes	8,405	5,210	3,415	1,867	844	19,741	+	+	
	Males	4,548	2,661	1,757	1,013	407	10,386	+	+	
	Females	3,856	2,549	1,657	855	437	9,355	+	+	
Hispanic	Both Sexes	21,339	14,049	8,272	4,881	2,136	50,676	+	+	
	Males	10,918	7,243	4,331	2,617	1,094	26,202	+	+	
	Females	10,421	6,805	3,941	2,264	1,043	24,474	+	+	

Estimated prevalence percent^a on January 1, 2016, of the SEER population diagnosed in the previous 24 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted ^c	
Race	Sex					30-39	40-49	50-59	60-69	70-79	80+	All Ages
All Races	Both Sexes	0.2001	0.0035	0.0139	0.0283	0.0538	0.1121	0.2352	0.4640	0.8181	1.0224	0.1738
	Males	0.2156	0.0044	0.0189	0.0354	0.0625	0.1293	0.2710	0.5243	0.9364	1.2449	0.2023
	Females	0.1850	0.0026	0.0087	0.0208	0.0450	0.0952	0.2010	0.4094	0.7196	0.8856	0.1498
White	Both Sexes	0.2216	0.0035	0.0143	0.0289	0.0534	0.1148	0.2427	0.4858	0.8597	1.0738	0.1807
	Males	0.2380	0.0045	0.0198	0.0359	0.0622	0.1317	0.2790	0.5442	0.9778	1.3060	0.2095
	Females	0.2054	0.0025	0.0085	0.0214	0.0442	0.0976	0.2072	0.4317	0.7593	0.9285	0.1560
Black	Both Sexes	0.1139	0.0029	0.0113	0.0265	0.0599	0.1027	0.2010	0.3340	0.5117	0.5333	0.1251
	Males	0.1226	0.0029	0.0140	0.0351	0.0696	0.1223	0.2333	0.3969	0.5849	0.6055	0.1457
	Females	0.1059	0.0030	0.0086	0.0178	0.0510	0.0853	0.1728	0.2836	0.4608	0.4976	0.1088
Asian/ Pacific Islander	Both Sexes	0.0970	0.0039	0.0133	0.0207	0.0353	0.0680	0.1409	0.2692	0.4470	0.6094	0.1032
	Males	0.1065	0.0044	0.0175	0.0240	0.0398	0.0744	0.1640	0.3072	0.5516	0.7472	0.1222
	Females	0.0882	0.0033	0.0092	0.0175	0.0312	0.0623	0.1209	0.2384	0.3629	0.5207	0.0880
Hispanic	Both Sexes	0.0887	0.0030	0.0117	0.0206	0.0398	0.0850	0.1769	0.3632	0.5888	0.7209	0.1294
	Males	0.0908	0.0035	0.0147	0.0256	0.0455	0.0932	0.1924	0.3940	0.6326	0.8003	0.1420
	Females	0.0866	0.0024	0.0086	0.0151	0.0337	0.0766	0.1616	0.3360	0.5552	0.6719	0.1185

^a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2016 US population estimates based on the average of 2015 and 2016 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Maximum limited-duration prevalence is 24 years for 1992-2016 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing 0 to <24 and >=24.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.